1 day Ago By ABMN Staff
AbbVie ( NYSE:ABBV – Get Free Report ) had its target price hoisted by investment analysts at Evercore ISI from $204.00 to $205.00 in a research report issued to clients and investors on Monday, Benzinga reports.
The firm currently has an “outperform” rating on the stock. Evercore ISI’s target price suggests a potential upside of 5.92% from the stock’s current price.
Several other research firms have also recently weighed in on ABBV. Truist Financial lifted their target price on AbbVie from $211.00 to $217.
00 and gave the company a “buy” rating in a research note on Monday, February 3rd. StockNews.com downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 9th.
Bank of America increased their target price on shares of AbbVie from $200.00 to $223.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th.
The Goldman Sachs Group restated a “neutral” rating and set a $194.00 price target on shares of AbbVie in a report on Tuesday, April 8th. Finally, Wells Fargo & Company increased their price objective on AbbVie from $210.
00 to $240.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and four have given a strong buy rating to the stock.
Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $211.41. Check Out Our Latest Stock Report on ABBV AbbVie Price Performance AbbVie ( NYSE:ABBV – Get Free Report ) last issued its quarterly earnings results on Friday, April 25th.
The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.40 by $0.
06. AbbVie had a net margin of 7.59% and a return on equity of 296.
28%. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.
91 billion. During the same quarter in the prior year, the firm earned $2.31 EPS.
The firm’s quarterly revenue was up 8.4% on a year-over-year basis. On average, analysts predict that AbbVie will post 12.
31 EPS for the current year. Insiders Place Their Bets In other news, EVP Perry C. Siatis sold 5,778 shares of the business’s stock in a transaction dated Thursday, February 20th.
The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20.
Following the transaction, the executive vice president now owns 22,381 shares in the company, valued at approximately $4,429,199.90. The trade was a 20.
52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website . Also, EVP Timothy J.
Richmond sold 29,917 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $202.90, for a total transaction of $6,070,159.
30. Following the completion of the sale, the executive vice president now owns 44,284 shares of the company’s stock, valued at approximately $8,985,223.60.
The trade was a 40.32 % decrease in their position. The disclosure for this sale can be found here .
Insiders have sold a total of 113,471 shares of company stock valued at $23,426,451 in the last three months. Company insiders own 0.25% of the company’s stock.
Institutional Investors Weigh In On AbbVie Several institutional investors and hedge funds have recently bought and sold shares of ABBV. Norges Bank acquired a new position in AbbVie in the fourth quarter worth about $4,459,385,000. GAMMA Investing LLC raised its holdings in shares of AbbVie by 25,841.
6% in the 1st quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company’s stock worth $2,144,382,000 after buying an additional 10,195,284 shares in the last quarter. Raymond James Financial Inc.
acquired a new position in shares of AbbVie in the 4th quarter worth approximately $1,190,951,000. FMR LLC boosted its stake in AbbVie by 32.8% in the 4th quarter.
FMR LLC now owns 18,097,375 shares of the company’s stock valued at $3,215,903,000 after buying an additional 4,466,971 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in AbbVie by 15.
1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 27,436,133 shares of the company’s stock valued at $4,875,401,000 after acquiring an additional 3,599,336 shares during the period.
Institutional investors own 70.23% of the company’s stock. AbbVie Company Profile ( Get Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Read More Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter .
.
